GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Float Percentage Of Total Shares Outstanding

BeiGene (SHSE:688235) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeiGene's float shares is 0.00 Mil. BeiGene's total shares outstanding is 1,474.58 Mil. BeiGene's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeiGene's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeiGene's Institutional Ownership is 3.15%.

BeiGene Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BeiGene's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/1,474.58
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeiGene (SHSE:688235) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
BNTX ALNY BMRN MRNA RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BGNE:USA 06160:Hong Kong 49BA:Germany B1GN34:Brazil
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (SHSE:688235) Headlines

No Headlines